Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic.

Pepperrell, Toby; Hill, Andrew; Moorhouse, Michelle; Clayden, Polly; McCann, Kaitlyn; Sokhela, Simiso; Serenata, Celicia; Venter, Willem Daniel Francois

Pepperrell, Toby; Hill, Andrew; Moorhouse, Michelle; Clayden, Polly; McCann, Kaitlyn; Sokhela, Simiso; Serenata, Celicia; Venter, Willem Daniel Francois.

Afiliação

Pepperrell T; Faculty of Medicine, Imperial College London, UK.
Hill A; Department of Translational Medicine, Liverpool University, Pharmacology, Liverpool, UK.
Moorhouse M; Ezintsha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Clayden P; HIV iBase, London, UK.
McCann K; Imperial College London, UK.
Sokhela S; Ezintsha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Serenata C; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Venter WDF; Ezintsha, Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

J Virus Erad ; 6(2): 70-73, 2020 Apr 30.

Article em En | MEDLINE | ID: mdl-32405424

Palavras-chave

HIV; antiretrovirals; black females; clinical trials; phase 3

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Risk_factors_studies Idioma: En Revista: J Virus Erad Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido País de publicação: Reino Unido

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google